You’re reading the latest from Dermatology Times. Our mission is to provide you with clinical insights that expand your expertise and advance your practice. Connect with us on Twitter and Facebook for daily updates.
When it comes to easily-recognized, benign, self-limited conditions like warts and molluscum, Dr. Siegfried calls herself a treatment nihilist. Learn why in this article.
New drugs in clinical trials for the treatment of warts and molluscum contagiosum could improve on currently available therapies, which are limited, used off-label and often cause tissue damage.
The Aesthetics Innovators Podcast provides an inside look into the most exciting approaches, strategies and companies in the industry. Join the conversation by subscribing today at https://attendais.com/podcast/
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: MultiMedia Healthcare
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA